- The first and only recombinant canarypox-vectored nonadjuvanted feline rabies vaccine
- The first and only half-mL feline rabies vaccine
- PUREVAX Feline Rabies Vaccine is available in both 1-year and 3-year duration of immunity preparations
- PUREVAX Feline Rabies 1-year is available in combination with PUREVAX® Feline 3 or PUREVAX® Feline 4 vaccines
PUREVAX® Feline Rabies
(rRabies 1 YR/rRabies 3 YR)
DETAILS
PUREVAX® Feline Rabies vaccines contain a nonadjuvanted lyophilized suspension of a recombinant vectored rabies vaccine plus a sterile water diluent. A canarypox vector has been modified using recombinant technology to produce expression of desired antigens capable of stimulating a protective immune response to rabies. Safety and immunogenicity of this product have been demonstrated by vaccination and challenge tests in susceptible cats.
INDICATIONS
PUREVAX® Feline Rabies 1 YR
This product has been shown to be effective for the vaccination of healthy cats, 12 weeks of age and older, against rabies virus. The duration of immunity is at least 1 year. For more information regarding efficacy and safety data, see productdata.aphis.usda.gov.
PUREVAX® Feline Rabies 3 YR
This product has been shown to be effective for the vaccination of healthy cats, 12 weeks of age and older, against rabies virus. The duration of immunity is at least 3 years. For more information regarding efficacy and safety data, see productdata.aphis.usda.gov.
DOSAGE & ADMINISTRATION
PUREVAX® Feline Rabies 1 YR: Aseptically rehydrate the lyophilized vaccine with the accompanying sterile diluent and agitate. Administer 1 dose subcutaneously into healthy cats. Revaccinate annually with a single dose.
PUREVAX® Feline Rabies 3 YR: Aseptically rehydrate the lyophilized vaccine with the accompanying sterile diluent and agitate. Administer 1 dose subcutaneously into healthy cats. Revaccinate one year after the first vaccination, then every three years with a single dose.
PRECAUTIONS
PUREVAX® Feline Rabies 1 YR
Precautions: Use entire contents immediately after reconstitution. Contains gentamicin as a preservative. This product has not been tested in pregnant animals. In rare instances, administration of vaccines may cause lethargy, fever, and inflammatory or hypersensitivity types of reactions. Treatment may include antihistamines, anti-inflammatories, and/or epinephrine. In case of human exposure, contact a physician. Inactivate unused contents before disposal.
Store at 2-8ºC (35-46ºF). Do not use chemicals to sterilize syringes and needles. Do not mix with other products, except as specified on the label.
For use in animals only. Restricted to use by or under the direction of a veterinarian.
PUREVAX® Feline Rabies 3 YR
Precautions: Use entire contents immediately after reconstitution. Contains gentamicin as a preservative. This product as not been tested in pregnant animals. In rare instances, administration of vaccines may cause lethargy, fever, and inflammatory or hypersensitivity types of reactions. Treatment may include antihistamines, anti-inflammatories, and/or epinephrine. In case of human exposure, contact a physician. Inactivate unused contents before disposal.
Store at 2-8ºC (35-46ºF). Do not use chemicals to sterilize syringes and needles. Do not mix with other products, except as specified on the label.
For use in animals only. Restricted to use by or under the direction of a veterinarian.
RECOMBITEK® Canine Vaccines
RECOMBITEK® vaccines are highly purified, making them a safe and effective option to help protect your canine patients from dangerous diseases.
IMRAB® Rabies Vaccines
Veterinarians worldwide trust US market-leading IMRAB® vaccines for proven multi-species rabies protection.6
PUREVAX® Feline Vaccines
Adjuvants can present potential risks to feline patients.1,7,8 PUREVAX® feline vaccines have been designed to elicit a protective immune response without the addition of adjuvants.
References
- Greene CE, Schultz RD. Immunoprophylaxis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. St Louis, MO: Elsevier Saunders; 2012:1166-1169.
- Taylor J, Meignier B, Tartglia J, et al. Biological and immunogenic properties of canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine. 1995; 13;6;539-549.
- PUREVAX® Feline 3/Rabies 1 YR Product Label.
- PUREVAX® Feline 4/Rabies 1 YR Product Label.
- Ma X, Monroe BP, Wallace RM, et al. Rabies surveillance in the United States 2019. J Am Vet Med Assoc. 2021;258(11):1205-1220. doi:10.2460/javma.258.11.1205.
- Data on file at Boehringer Ingelheim.
- McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol. 2018;141(2):463-472.
- Day MJ, Schoon H-A, Magnol J-P, et al. A kinetic study of histopathological changes in the subcutis of cats injected with non-adjuvanted and adjuvanted multi-component vaccines. Vaccine. 2007; 25:4073-4084.
Trademarks
RECOMBITEK® and IMRAB® are registered trademarks and BI-CONNECT™ is a trademark of Boehringer Ingelheim Animal Health USA Inc. PUREVAX® is a registered trademark of Boehringer Ingelheim Animal Health France, used under license. ©2023 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved.
US-PET-0234-2021-C-V2